Literature DB >> 17480178

Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.

Georg B Ehret1, Jules A Desmeules, Barbara Broers.   

Abstract

Methadone is used as the pharmacologic mainstay for substitution for illegal opiates and as analgesic for chronic or cancer-related pain. Given the benefits of methadone substitution for illicit opioids, the finding of an association between methadone and prolongation of cardiac depolarization (QT prolongation) and torsades de pointes is of great concern. QT prolongation can occur with many drugs and is a potentially lethal adverse drug reaction, necessitating risk monitoring and therapeutic alternatives in some patients. Recent studies suggest that QT prolongation with methadone is context dependent: occurrence is more frequent with high doses of methadone, concomitant administration of CYP3A4 inhibitors, hypokalemia, hepatic failure, administration of other QT prolonging drugs and pre-existing heart disease. The valued benefit of methadone substitution therapy on the one hand and the increased cardiovascular risk in particular situations on the other illustrate the difficulties in dealing with drug-induced QT prolongation in general.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17480178     DOI: 10.1517/14740338.6.3.289

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  17 in total

1.  ACMT Position Statement: The Use of Methadone as an Analgesic.

Authors: 
Journal:  J Med Toxicol       Date:  2016-06

Review 2.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

3.  Bi-ventricular failure following methadone overdose.

Authors:  Laurens Mitchell Heggs; Olivier Genée; Jérôme Fichet
Journal:  Intensive Care Med       Date:  2008-04-22       Impact factor: 17.440

Review 4.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

5.  Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Authors:  Sheng-Chang Wang; Ing-Kang Ho; Hsiao-Hui Tsou; Sheng-Wen Liu; Chin-Fu Hsiao; Chia-Hui Chen; Happy Kuy-Lok Tan; Linen Lin; Chi-Shin Wu; Lien-Wen Su; Chieh-Liang Huang; Yi-Hong Yang; Ming-Lun Liu; Keh-Ming Lin; Shu Chih Liu; Hsiao-Yu Wu; Hsiang-Wei Kuo; Andrew C H Chen; Yao-Sheng Chang; Yu-Li Liu
Journal:  OMICS       Date:  2013-09-09

6.  Ventricular bigeminy associated with voriconazole, methadone and esomeprazole.

Authors:  Julie Scholler; Yasmine Nivoix; Raoul Herbrecht; Véronique Kemmel; Dominique Levêque
Journal:  Int J Clin Pharm       Date:  2011-11-23

7.  Torsades de pointes associated with methadone and voriconazole.

Authors:  Jennifer A Reinhold; Cynthia A Sanoski; Andrea M Russo; Joshua M Cooper; Sarah A Spinler
Journal:  BMJ Case Rep       Date:  2009-12-22

8.  Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.

Authors:  Annemarie Unger; Erika Jung; Bernadette Winklbaur; Gabriele Fischer
Journal:  J Addict Dis       Date:  2010-04

Review 9.  Methadone deaths: risk factors in pain and addicted populations.

Authors:  Vania Modesto-Lowe; Donna Brooks; Nancy Petry
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

10.  A meta-analysis of retention in methadone maintenance by dose and dosing strategy.

Authors:  Yan-Ping Bao; Zhi-Min Liu; David H Epstein; Cun Du; Jie Shi; Lin Lu
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.